Showing results (61-70 of 92) with videos related to
Sort By:
Pageof 10
Drugs in R&D|June 3, 2017
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular CarcinomaTakuya Sho, Mitsuru Nakanishi, Kenichi Morikawa, et al.Journal of Gastroenterology and Hepatology|April 20, 2011
Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiationMakoto Chuma, Hiroshi Taguchi, Yoshiya Yamamoto, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 2, 2019
Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysisKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.Plos One|January 20, 2022
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis BKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.Viruses|January 21, 2023
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis CNaoki Kawagishi, Goki Suda, Yoshiya Yamamoto, et al.Journal of Physics. Condensed Matter : an Institute of Physics Journal|April 23, 2021
Electronic and crystal structures of<i>Ln</i>FeAsO<sub>1-</sub>H<sub></sub>(<i>Ln</i>= La, Sm) studied by x-ray absorption spectroscopy, x-ray emission spectroscopy, and x-ray diffraction: II pressure dependenceYoshiya Yamamoto, Hitoshi Yamaoka, Takuma Kawai, et al.Journal of Physics. Condensed Matter : an Institute of Physics Journal|April 20, 2021
Electronic and crystal structures of<i>Ln</i>FeAsO<sub>1-</sub>H<sub></sub>(<i>Ln</i>= La, Sm) studied by x-ray absorption spectroscopy, x-ray emission spectroscopy, and x-ray diffraction (part I: carrier-doping dependence)Yoshiya Yamamoto, Hitoshi Yamaoka, Takayuki Uozumi, et al.Targeted Oncology|September 2, 2024
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab TreatmentTakuya Sho, Goki Suda, Masatsugu Ohara, et al.Journal of Gastroenterology|March 20, 2017
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapyGoki Suda, Koji Ogawa, Yoshiya Yamamoto, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2016
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infectionJun Ito, Goki Suda, Yoshiya Yamamoto, et al.Pageof 10